SERPING1 and myeloid sarcoma: Reduction of FX, prothrombin and C1INH levels in pre- and post-symptomatic MS serum. Reduction in FXIII and plasminogen in post-symptomatic MS (Mass spectrometry (pooled serum of 100 MS vs. pooled serum of 100 controls).